Compare NIO Inc. (NIO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs Twist Bioscience Corp — how do they compare? NIO Inc. trades at $3.65 (market cap $9.23B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: NIO Inc. and Twist Bioscience Corp are close in size by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| NIO | TWST | |
|---|---|---|
Market Cap | $9.23B | $8.42B |
Sector | Consumer Cyclical | Health |
52-Week High | $7.89 | $153.10 |
52-Week Low | $3.70 | $24.16 |
Enterprise Value | $7.13B | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.79, down 0.26% over 24 hours, with a bearish technical signal but improving fundamentals. Recent Q2 2026 earnings beat expectations with a narrower loss, while revenue grew 69.1% year-over-year to $4.74 billion (Seeking Alpha, 2026-09-03). The stock faces headwinds from a weak Chinese EV market but shows progress toward profitability with positive operating cash flow in Q2.
The outlook is mixed: analyst consensus is bullish with a $5.50 price target (50% buy ratings), but risks include high debt, competition, and macroeconomic pressures. Upside depends on sustained delivery growth and margin expansion, while downside risks loom from cost inflation and market sentiment shifts.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
